{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:31:00Z","timestamp":1789381860665,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Kingdom of Morocco approved BBIBP-CorV (Sinopharm) COVID-19 vaccine for emergency use on 22 January 2021 in a two-dose, three-to-four-week interval schedule. We conducted a retrospective cohort study to determine real-world BBIBP-CorV vaccine effectiveness (VE) against serious or critical hospitalization of individuals RT-PCR-positive for SARS-CoV-2 during the first five months of BBIBP-CorV use in Morocco.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted among adults 18\u201399\u00a0years old who were tested by RT-PCR for SARS-CoV-2 infection between 1 February and 30 June 2021. RT-PCR results were individually linked with outcomes from the COVID-19 severe or critical hospitalization dataset and with vaccination histories from the national vaccination registration system. Individuals with partial vaccination (&lt;\u20092\u00a0weeks after dose two) or in receipt of any other COVID-19 vaccine were excluded. Unadjusted and adjusted VE estimates against hospitalization for serious or critical illness were made by comparing two-dose vaccinated and unvaccinated individuals in logistic regression models, calculated as (1-odds ratio) * 100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 348,190 individuals able to be matched across the three databases. Among these, 140,892 were fully vaccinated, 206,149 were unvaccinated, and 1,149 received homologous BBIBP-CorV booster doses. Unadjusted, full-series, unboosted BBIBP-CorV VE against hospitalization for serious or critical illness was 90.2% (95%CI: 87.8\u201492.0%). Full-series, unboosted VE, adjusted for age, sex, and calendar day of RT-PCR test, was 88.5% (95%CI: 85.8\u201490.7%). Calendar day- and sex-adjusted VE was 96.4% (95%CI: 94.6\u201497.6%) for individuals\u2009&lt;\u200960\u00a0years, and was 53.3% (95%CI: 39.6\u201463.9%) for individuals 60\u00a0years and older. There were no serious or critical illnesses among BBIBP-CorV-boosted individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Effectiveness of Sinopharm\u2019s BBIBP-CorV was consistent with phase III clinical trial results. Two doses of BBIBP-CorV was highly protective against COVID-19-associated serious or critical hospitalization in working-age adults under real-world conditions and moderately effective in older adults. Booster dose vaccination was associated with complete protection, regardless of age, although only a small proportion of subjects received booster doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-022-14016-9","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T08:02:54Z","timestamp":1660982574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco"],"prefix":"10.1186","volume":"22","author":[{"given":"Yaowen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Belayachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Rodewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdouline","family":"Obtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Mhayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Razine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Abouqal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"14016_CR1","unstructured":"World Health Organization. Coronavirus (COVID-19) dashboard (2021). https:\/\/covid19.who.int\/. Accessed 22 Apr 2022."},{"key":"14016_CR2","unstructured":"World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 22 Apr 2022."},{"key":"14016_CR3","unstructured":"World Health Organization. Vaccination data (2021). https:\/\/covid19.who.int\/who-data\/vaccination-data.csv. Accessed 22 Apr 2022."},{"key":"14016_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713\u201321.","journal-title":"Cell"},{"key":"14016_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951\u201360.","journal-title":"JAMA"},{"key":"14016_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21:39\u201351.","journal-title":"Lancet Infect Dis"},{"key":"14016_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35\u201345.","journal-title":"JAMA"},{"key":"14016_CR8","unstructured":"World Health Organization. WHO recommendation COVID-19 Vaccine BIBP\/Sinopharm (2021). https:\/\/extranet.who.int\/pqweb\/vaccines\/who-recommendation-covid-19-vaccine-bibp. Accessed 22 Apr 2022."},{"key":"14016_CR9","unstructured":"CGTN. Morocco approves emergency use of China's Sinopharm COVID-19 vaccine (2021). https:\/\/news.cgtn.com\/news\/2021-01-24\/Morocco-approves-emergency-use-of-China-s-Sinopharm-COVID-19-vaccine--XjzvHTjxfy\/index.html. Accessed 22 Apr 2022."},{"key":"14016_CR10","unstructured":"Morocco acquires the first batch of the vaccine against the Covid-19 virus (2021). https:\/\/www.sante.gov.ma\/pages\/actualites.aspx?idactu=431. Accessed 22 Apr 2022."},{"key":"14016_CR11","unstructured":"International vaccine access center, Johns Hopkins Bloomberg school of Public Health, World Health Organization. Results of COVID-19 vaccine effectiveness studies: an ongoing systematic review. https:\/\/view-hub.org\/resources. Accessed 05 Jul 2022."},{"key":"14016_CR12","unstructured":"Ministerio de Salud Argentina. Estudio efectividad de campa\u00f1a nacional de vacunaci\u00f3n en reducci\u00f3n de la mortalidad por COVID-19 en personas de 60 a\u00f1os y mayores (2021). https:\/\/www.argentina.gob.ar\/sites\/default\/files\/2021\/04\/2021-06-30-efectividad-para-prevenir-mortalidad-vacuna-covid19-mayores-60.pdf. Accessed 22 Apr 2022."},{"key":"14016_CR13","unstructured":"Ministerio de Salud Argentina. Reuni\u00f3n de la Comisi\u00f3n Nacional de Inmunizaci\u00f3n. https:\/\/www.argentina.gob.ar\/sites\/default\/files\/2021\/04\/2021-06-30-acta-conain_0.pdf. Accessed 05 Jul 2022."},{"key":"14016_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cmi.2021.11.011","volume":"28","author":"Z Vok\u00f3","year":"2022","unstructured":"Vok\u00f3 Z, Kiss Z, Surj\u00e1n G, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect. 2022;28:398\u2013404.","journal-title":"Clin Microbiol Infect"},{"key":"14016_CR15","doi-asserted-by":"crossref","unstructured":"Ismail AlHosani F, Eduardo Stanciole A, Aden B, et al. Impact of the Sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine. 2022;40:2003\u201310.","DOI":"10.1016\/j.vaccine.2022.02.039"},{"key":"14016_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412\u201323.","journal-title":"N Engl J Med"},{"key":"14016_CR17","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, Mclaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819\u201329.","journal-title":"Lancet"},{"key":"14016_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385:1355\u201371.","journal-title":"N Engl J Med"},{"key":"14016_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1943","volume":"374","author":"H Chung","year":"2021","unstructured":"Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374: n1943.","journal-title":"BMJ"},{"key":"14016_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the (Delta) Variant. N Engl J Med. 2021;385:585\u201394.","journal-title":"N Engl J Med."},{"key":"14016_CR21","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","volume":"397","author":"E Vasileiou","year":"2021","unstructured":"Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397:1646\u201357.","journal-title":"Lancet"},{"key":"14016_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/S1473-3099(21)00330-3","volume":"21","author":"C Hyams","year":"2021","unstructured":"Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21:1539\u201348.","journal-title":"Lancet Infect Dis"},{"key":"14016_CR23","doi-asserted-by":"publisher","unstructured":"Bernal J L, Andrews N, Gower C, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.05.14.21257218.","DOI":"10.1101\/2021.05.14.21257218"},{"key":"14016_CR24","doi-asserted-by":"publisher","unstructured":"De Gier B, Kooijman M, Kemmeren J, et al. COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands. 2021. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.09.15.21263613.","DOI":"10.1101\/2021.09.15.21263613"},{"key":"14016_CR25","doi-asserted-by":"publisher","unstructured":"Moustsen-Helms IR, Emborg H-D, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers \u2013 a Danish cohort study. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.03.08.21252200.","DOI":"10.1101\/2021.03.08.21252200"},{"key":"14016_CR26","doi-asserted-by":"publisher","unstructured":"Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.03.16.21253686.","DOI":"10.1101\/2021.03.16.21253686"},{"key":"14016_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417\u201322.","journal-title":"Nature"},{"key":"14016_CR28","doi-asserted-by":"publisher","unstructured":"Emborg H-D, Valentiner-Branth P, Schelde AB, et al. Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.05.27.21257583.","DOI":"10.1101\/2021.05.27.21257583"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-14016-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T08:03:06Z","timestamp":1660982586000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-14016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14016"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-14016-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.23.22274112","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Rabat Ethics Committee for Biomedical Research, University Mohammed V, Faculty of Medicine (Rabat, Morocco). A waiver of informed consent was granted for this observational study. Authorization from the National Control Commission for the Protection of Personal Data (CNDP) was also obtained. All methods were performed in accordance with the relevant guidelines and regulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yaowen Zhang, Yunkai Yang, Hongling Li, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Tianfang Xu, Yuntao Zhang and Xiaoming Yang are employees of China National Biotec Group Company Limited. Qiang Fu, Bing Yan, Ying Wang and Chen Su are employees of China Sinopharm International Corporation. Both companies are wholly-owned subsidiaries of China National Pharmaceutical Group Co., Ltd. (Sinopharm). The rest of the authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1584"}}